Paper Details

  1. Home
  2. Paper Details

The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism.

Author: Arellano-RodrigoEduardo, Diaz-RicartMaribel, EscolarGines, GalánAna M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article discusses the emergence of new oral anticoagulants as more convenient and effective alternatives to traditional antithrombotic strategies for managing thromboembolic diseases.
Paper Details　
Original Abstract of the Article :
Thromboembolic diseases will become the most important contributors to mortality and morbidity for modern societies. Current antithrombotic strategies using heparins or vitamin K antagonists are inconvenient, with limitations and inherent side effects. A series of new oral anticoagulants with powerf...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/17425255.2014.882897

データ提供：米国国立医学図書館（NLM）

Edoxaban: A New Era in Venous Thromboembolism Prevention and Treatment

The ever-growing burden of thromboembolic diseases demands innovative approaches to prevention and treatment. This research explores the pharmacokinetics of edoxaban, a new oral anticoagulant, for the prevention and treatment of venous thromboembolism. The authors highlight the limitations of traditional antithrombotic strategies, such as heparins and vitamin K antagonists, emphasizing the need for new and more effective options. They delve into the development of a series of novel oral anticoagulants, including edoxaban, offering promising advancements in the management of thromboembolic diseases.

Edoxaban: A Promising New Anticoagulant

The study explores the pharmacokinetics of edoxaban, a new oral anticoagulant, for the prevention and treatment of venous thromboembolism. The authors highlight the potential of edoxaban as a safe and effective alternative to traditional anticoagulants, offering promising advancements in the management of thromboembolic diseases.

Navigating Thromboembolic Diseases: Edoxaban as a Potential Solution

The research emphasizes the importance of exploring new and effective anticoagulants, such as edoxaban, for managing thromboembolic diseases. The authors suggest that edoxaban, with its favorable pharmacokinetic profile and potential for improved efficacy and safety, could be a valuable addition to the treatment options available for venous thromboembolism.

Dr. Camel's Conclusion

This research underscores the importance of developing new and effective anticoagulants, such as edoxaban, for managing thromboembolic diseases. The authors highlight the potential of edoxaban as a safe and effective alternative to traditional anticoagulants, offering hope for individuals facing the challenges of thromboembolic diseases.

Date :
  1. Date Completed 2015-01-26
  2. Date Revised 2016-11-25
Further Info :

Pubmed ID

24471416

DOI: Digital Object Identifier

10.1517/17425255.2014.882897

Related Literature

Article Analysis
・Side Effects of edoxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.